Ferrets: A powerful model of SARS-CoV-2

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in recent years not only caused a global pandemic but resulted in enormous social, economic, and health burdens worldwide. Despite considerable efforts to combat coronavirus disease 2019 (COVID-19), various SARS-CoV-2 variants have emerged, and their underlying mechanisms of pathogenicity remain largely unknown. Furthermore, effective therapeutic drugs are still under development. Thus, an ideal animal model is crucial for studying the pathogenesis of COVID-19 and for the preclinical evaluation of vaccines and antivirals against SARS-CoV-2 and variant infections. Currently, several animal models, including mice, hamsters, ferrets, and non-human primates (NHPs), have been established to study COVID-19. Among them, ferrets are naturally susceptible to SARS-CoV-2 infection and are considered suitable for COVID-19 study. Here, we summarize recent developments and application of SARS-CoV-2 ferret models in studies on pathogenesis, therapeutic agents, and vaccines, and provide a perspective on the role of these models in preventing COVID-19 spread.

[1]  Xiaoqun Wang,et al.  Single-nucleus transcriptomic profiling of multiple organs in a rhesus macaque model of SARS-CoV-2 infection , 2022, Zoological research.

[2]  Hyunggee Kim,et al.  SARS-CoV-2 variants show temperature-dependent enhanced polymerase activity in the upper respiratory tract and high transmissibility , 2022, bioRxiv.

[3]  Troy J. Kieran,et al.  Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model , 2022, mBio.

[4]  R. Plemper,et al.  SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model , 2022, Nature Communications.

[5]  R. De Francesco,et al.  DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model , 2022, Vaccines.

[6]  A. Y. Ye,et al.  Generation of a live attenuated influenza A vaccine by proteolysis targeting , 2022, Nature Biotechnology.

[7]  M. Zeng,et al.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants , 2022, Signal Transduction and Targeted Therapy.

[8]  Linhui Hao,et al.  Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants , 2022, bioRxiv.

[9]  Q. Lin,et al.  Animal models for studying coronavirus infections and developing antiviral agents and vaccines , 2022, Antiviral Research.

[10]  S. Lowther,et al.  Characterisation and natural progression of SARS-CoV-2 infection in ferrets , 2022, Scientific Reports.

[11]  Hailiang Sun,et al.  Systematic Tracing of Susceptible Animals to SARS-CoV-2 by a Bioinformatics Framework , 2022, Frontiers in Microbiology.

[12]  Eun Ji Kim,et al.  Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets , 2021, Nature Communications.

[13]  B. Hoffmann,et al.  Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta , 2021, Nature.

[14]  R. Plemper,et al.  Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets , 2021, Nature Communications.

[15]  Mi-ha Im,et al.  Antiviral effects of human placenta hydrolysate (Laennec®) against SARS-CoV-2 in vitro and in the ferret model , 2021, Journal of Microbiology.

[16]  G. Ciliberto,et al.  COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models , 2021, Molecular Therapy.

[17]  Chang-Seon Song,et al.  COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity , 2021, Vaccines.

[18]  M. H. Fernandes,et al.  Age-Related Susceptibility of Ferrets to SARS-CoV-2 Infection , 2021, bioRxiv.

[19]  M. Cameron,et al.  Sex and age bias viral burden and interferon responses during SARS-CoV-2 infection in ferrets , 2021, Scientific Reports.

[20]  N. Petrovsky,et al.  Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection , 2021, bioRxiv.

[21]  P. Roholl,et al.  Pathology and Immunity After SARS-CoV-2 Infection in Male Ferrets Is Affected by Age and Inoculation Route , 2021, bioRxiv.

[22]  R. Tripp,et al.  Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo , 2021, Antiviral Research.

[23]  B. Cong,et al.  Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza , 2021, Signal Transduction and Targeted Therapy.

[24]  W. Horman,et al.  ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets , 2021, npj Vaccines.

[25]  X. Qiu,et al.  The Ferret as a Model for Filovirus Pathogenesis and Countermeasure Evaluation. , 2021, ILAR journal.

[26]  P. Moore,et al.  Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant , 2021, bioRxiv.

[27]  M. Giacca,et al.  The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets , 2021, Nature Microbiology.

[28]  J. Runstadler,et al.  Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-exposure domestic setting , 2021, Proceedings of the National Academy of Sciences.

[29]  D. Sim,et al.  Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate , 2021, Journal of virology.

[30]  S. Vasan,et al.  Metabolic Profiling from an Asymptomatic Ferret Model of SARS-CoV-2 Infection , 2021, Metabolites.

[31]  Jae U. Jung,et al.  Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets , 2021, mBio.

[32]  M. Beer,et al.  SARS-CoV-2 spike D614G change enhances replication and transmission , 2021, Nature.

[33]  R. Plemper,et al.  4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication , 2021, Science.

[34]  F. Gleeson,et al.  ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models , 2021, Communications biology.

[35]  C. Turner,et al.  Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity , 2021, Nature Communications.

[36]  I. Brown,et al.  Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection , 2021, Viruses.

[37]  Eun Ji Kim,et al.  Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission , 2021, Emerging microbes & infections.

[38]  T. Bestebroer,et al.  SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance , 2020, Nature Communications.

[39]  R. Plemper,et al.  Therapeutically Administered Ribonucleoside Analogue MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets , 2020, Nature microbiology.

[40]  C. Alabi,et al.  Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets , 2020, bioRxiv.

[41]  M. Mohan,et al.  Animal Models for SARS-CoV-2 research: A Comprehensive Literature Review. , 2020, Transboundary and emerging diseases.

[42]  Xiaohong Song,et al.  A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge , 2020, Nature Communications.

[43]  Yong-tang Zheng,et al.  Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques , 2020, Zoological research.

[44]  Chengbo He,et al.  Single‐cell RNA sequencing analysis of human kidney reveals the presence of ACE2 receptor: A potential pathway of COVID‐19 infection , 2020, Molecular genetics & genomic medicine.

[45]  Yong-tang Zheng,et al.  COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2 , 2020, Zoological research.

[46]  R. Fonseca,et al.  Targeting TMPRSS2 in SARS-CoV-2 Infection , 2020, Mayo Clinic Proceedings.

[47]  W. Zuo,et al.  Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2 , 2020, American journal of respiratory and critical care medicine.

[48]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[49]  Zhe Zheng,et al.  Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart , 2020, Cardiovascular research.

[50]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[51]  Rongchang Chen,et al.  Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment , 2020, Cell.

[52]  G. Gao,et al.  Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.

[53]  Eric Song,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, bioRxiv.

[54]  T. Zhao,et al.  A Mouse Model of SARS-CoV-2 Infection and Pathogenesis , 2020, Cell Host & Microbe.

[55]  H. Gao,et al.  Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 via Close Contact and Respiratory Droplets Among Human Angiotensin-Converting Enzyme 2 Mice , 2020, The Journal of Infectious Diseases.

[56]  Eun Ji Kim,et al.  Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets , 2020, mBio.

[57]  P. Zhou,et al.  Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2 , 2020, Cell.

[58]  H. Yen,et al.  Pathogenesis and transmission of SARS-CoV-2 in golden hamsters , 2020, Nature.

[59]  M. Koopmans,et al.  SARS-CoV-2 is transmitted via contact and via the air between ferrets , 2020, bioRxiv.

[60]  T. Kuiken,et al.  Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.

[61]  Baoying Huang,et al.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.

[62]  Eun-Ha Kim,et al.  Infection and Rapid Transmission of SARS-CoV-2 in Ferrets , 2020, Cell Host & Microbe.

[63]  K. To,et al.  Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[65]  Wenling Wang,et al.  Age‐related rhesus macaque models of COVID‐19 , 2020, Animal models and experimental medicine.

[66]  A. Schuchat,et al.  COVID-19: towards controlling of a pandemic , 2020, The Lancet.

[67]  P. Zhou,et al.  Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques , 2020, Cell Research.

[68]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[69]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[70]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[71]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[72]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[73]  A. García-Sastre,et al.  Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection , 2020, Emerging microbes & infections.

[74]  T. Maines,et al.  Ferreting Out Influenza Virus Pathogenicity and Transmissibility: Past and Future Risk Assessments in the Ferret Model. , 2019, Cold Spring Harbor perspectives in medicine.

[75]  R. Plemper,et al.  Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia , 2019, Science Translational Medicine.

[76]  S. Kent,et al.  Improving immunological insights into the ferret model of human viral infectious disease , 2019, Influenza and other respiratory viruses.

[77]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[78]  A. Osterhaus,et al.  Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts , 2016, Viruses.

[79]  S. van Drunen Littel-van den Hurk,et al.  Pathogenesis of respiratory syncytial virus. , 2012, Current opinion in virology.

[80]  John M. Walker,et al.  Metabolic Profiling , 2011, Methods in Molecular Biology.

[81]  David K Meyerholz,et al.  Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. , 2010, The Journal of clinical investigation.

[82]  T. Kuiken,et al.  Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets , 2008, Veterinary pathology.

[83]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[84]  J. Bartlett Virology: SARS virus infection of cats and ferrets , 2004 .

[85]  A. Konstantinos,et al.  A Comparative Assessment , 2003 .

[86]  G. Prince,et al.  The pathogenesis of respiratory syncytial virus infection in infant ferrets. , 1976, The American journal of pathology.